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Architecture of the RNA polymerase II-Paf1C-TFIIS
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The conserved polymerase-associated factor 1 complex (Paf1C) plays multiple roles in
chromatin transcription and genomic regulation. Paf1C comprises the ﬁve subunits Paf1, Leo1,
Ctr9, Cdc73 and Rtf1, and binds to the RNA polymerase II (Pol II) transcription elongation
complex (EC). Here we report the reconstitution of Paf1C from Saccharomyces cerevisiae, and a
structural analysis of Paf1C bound to a Pol II EC containing the elongation factor TFIIS.
Cryo-electron microscopy and crosslinking data reveal that Paf1C is highly mobile and
extends over the outer Pol II surface from the Rpb2 to the Rpb3 subunit. The Paf1-Leo1
heterodimer and Cdc73 form opposite ends of Paf1C, whereas Ctr9 bridges between them.
Consistent with the structural observations, the initiation factor TFIIF impairs Paf1C binding to
Pol II, whereas the elongation factor TFIIS enhances it. We further show that Paf1C is globally
required for normal mRNA transcription in yeast. These results provide a three-dimensional
framework for further analysis of Paf1C function in transcription through chromatin.
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T
he polymerase-associated factor 1 (Paf1) complex (Paf1C)
is a general and conserved RNA polymerase II (Pol II)
transcription elongation factor1. Paf1C was ﬁrst identiﬁed
through its copuriﬁcation with Pol II from yeast cells2,3. Yeast
Paf1C comprises the subunits Paf1, Leo1, Ctr9, Cdc73 and Rtf1
(refs 1,4). Paf1C shows genetic interactions with the yeast
transcription elongation factors Spt4-Spt5 and Spt16-Pob3, the
counterparts of human DSIF and FACT, respectively5. Paf1C also
associates with transcribed regions in vivo6, suggesting that it is a
transcription elongation factor. Paf1C subunits are required for
efﬁcient transcription in vivo7.
Paf1C has multiple roles in chromatin transcription. Yeast
Paf1C functions in methylation of histone H3 by Set1 and Dot1,
thus linking transcription elongation to chromatin methylation8.
In yeast, Rtf1 binds the chromatin remodeller Chd1 (ref. 9) and is
required for ubiquitination of histone H2B (refs 10–12) and
histone methylation13. Drosophila Rtf1 also functions in histone
methylation, gene expression and Notch signalling14. Human
Paf1C binds to histone H3 tails with dimethylated histone H3
arginine17 (ref. 15).
Paf1C also has important functions that are not directly related
to chromatin. Paf1C is required for cotranscriptional RNA
30-processing16,17. Human Cdc73 physically interacts with
protein complexes required for 30-processing18. Paf1C also
represses cryptic transcription19 and is implicated in cellular
differentiation20 and human cancer21–23. Paf1C represses gene
silencing by small RNAs in Schizosaccharomyces pombe24, and
Leo1 is involved in heterochromatin spreading25. Paf1C has
recently been found to regulate Pol II phosphorylation,
promoter–proximal pausing and release into gene bodies26,27.
Paf1C is also involved in the resolution of transcription–
replication conﬂicts28.
Paf1C is generally recruited to transcribed units, apparently
entering the Pol II elongation complex (EC) downstream of the
transcription start site, and exiting at the polyadenylation (pA)
site29. There is evidence that Paf1C recruitment to Pol II requires
direct contacts with Pol II and additional contacts with Pol II-
associated factors. Paf1C recruitment in vivo requires the Bur1-
Bur2 kinase30, and is aided by Spt4 (ref. 31). Paf1C and its Cdc73
subunit bind the phosphorylated C-terminal domain of Pol II and
the phosphorylated C-terminal repeat region (CTR) of Spt5,
which is also a general elongation factor32. A Plus3 domain in
Rtf1 can bind the Spt5 CTR33. Rtf1 is however not stably
associated with Paf1C in all species and is not required for Paf1C
recruitment in human cells, where it has non-overlapping
functions34. In ﬁssion yeast, Rtf1 also has other functions35.
The C-terminal GTPase-like domain of Cdc73 is important for
chromatin association of Paf1C (ref. 36). Leo1 is also important
for Paf1C recruitment and binds RNA37.
Structural studies have revealed that Paf1C is a modular and
ﬂexible complex with several structured regions. The crystal
structure of a complex of regions in Paf1 and Leo1 revealed
antiparallel b-sheets for heterodimerization38. This study also
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Figure 1 | Preparation of recombinant Paf1C. (a) Predicted domain structure of the ﬁve Paf1C subunits from S. cerevisiae. The predicted tetratrico peptide
repeat motifs (yellow) and low complexity regions (green) were deﬁned using SMART42. Structurally resolved regions are indicated with black lines. The
Plus3 domain in Rtf1 (red) binds single-stranded DNA40 and the Spt5 CTR41. A Paf1C-interacting region (orange) in Rtf1 (ref. 13) was conﬁrmed in this
work. Histone modiﬁcation domain (HMD, pink) in Rtf1 directly contacts ubiquitin conjugase Rad6 in vivo44. (b) Size-exclusion chromatogram (Superose 6
10/300; GE Healthcare) of recombinant full-length Paf1C indicates a pure complex free of nucleic acids. (c) Coomassie-stained SDS–PAGE analysis of
recombinant ﬁve-subunit Paf1C after size-exclusion chromatography reveals the presence of all ﬁve subunits in apparently stoichiometric amounts.
Molecular weight markers are indicated on the left. The identity of subunits was conﬁrmed by mass spectrometry. (d) Same as c but for puriﬁed complex
Paf1C-Ctr9-DC913.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15741
2 NATURE COMMUNICATIONS | 8:15741 | DOI: 10.1038/ncomms15741 | www.nature.com/naturecommunications
Leo1 heterodimer and Cdc73 assemble. The structure of the
GTPase-like domain in the C-terminal region of yeast Cdc73 was
also solved36,39. In addition, structures were reported for the
Plus3 domain of human Rtf1 (refs 40,41), and for the Plus3
domain in complex with a phosphorylated Spt5 CTR repeat41.
There is however no structural information on Ctr9, the largest
Paf1C subunit.
Despite its critical role in chromatin transcription and
transcription-coupled events, neither the structure of Paf1C nor
its location on the Pol II EC are known. Here we reconstitute
yeast Paf1C from recombinant subunits, assemble a complex of
Paf1C with the Pol II-TFIIS EC and locate Paf1C on the
polymerase surface with a combination of electron microscopy
(EM) and crosslinking. From this work emerges a trilobal
architecture of Paf1C and the location of Paf1C on the elongating
polymerase, providing a basis for a mechanistic analysis of
transcription elongation through chromatin.
Results
Recombinant Paf1C. Paf1C from the yeast Saccharomyces cere-
visiae (S. cerevisiae) has a molecular weight of 340 kDa and
consists of ﬁve subunits, Paf1, Leo1, Ctr9, Cdc73 and Rtf1
(Fig. 1a). Analysis of the primary and secondary structures of
these subunits42,43 predicted known structured domains36,38–41,44
and eight tetratrico peptide repeats in Ctr9 (Fig. 1a). In addition,
multiple regions of low sequence complexity were detected in all
Paf1C subunits except Cdc73, consistent with the known
ﬂexibility of Paf1C (Supplementary Fig. 1a). To study Paf1C
structurally, we established preparation of pure recombinant
Paf1C after coexpression of its subunits in Escherichia coli
(E. coli) (see Fig. 1b,c and Methods section). The ﬁve Paf1C
subunits were coexpressed from three vectors in E. coli and the
complex puriﬁed using chromatographic methods (see Fig. 1b
and Methods section). We obtained B0.4mg of pure Paf1C per
liter of E. coli cell culture. Puriﬁed Paf1C contained all ﬁve
subunits in apparently stoichiometric amounts (Fig. 1c).
Paf1C structural core and ﬂexible periphery. To map a stable
structural core of Paf1C, we identiﬁed a Ctr9 variant that lacked
164 amino acids at its C terminus (Ctr9-DC913), but was sufﬁ-
cient to form a stable complex with the other subunits after
coexpression (Paf1C-Ctr9-DC913) (Fig. 1d). We also obtained a
recombinant Paf1C variant that additionally lacked subunit Rtf1
(Paf1C-Ctr9-DC913-DRtf1; Supplementary Fig. 1b). To further
delineate the core of Paf1C, we used limited proteolysis and
Edman sequencing (see Supplementary Fig. 1a and Methods
section) and designed deletion mutants of the remaining three
subunits. The limited proteolysis also showed that Leo1 and Paf1
are unstable. Combining iterative truncations of Leo1, Paf1 and
Ctr9-DC-913, coexpression and copuriﬁcation, we deﬁned a
structural core of Paf1C that additionally lacked the C-terminal
region of Paf1 and both terminal regions of Leo1.
The resulting Paf1C core contained Ctr9-DC913, Paf1-DC361,
Leo1-DN118-DC376 and Cdc73 (Supplementary Fig. 1c). The
deﬁned Paf1C core comprises 1,926 amino-acid residues out of a
total of 2,937 residues, that is, 65% of the total protein mass.
Thus, one-third of Paf1C forms ﬂexible regions on the periphery
of the complex. The C-terminal region of Rtf1 (Rtf1-DN441) can
interact with the Paf1C core, indicating that the C-terminal
region of Paf1 and both terminal regions of Leo1 are not crucial
for Rtf1 binding (Supplementary Fig. 1d). In addition, we
expressed and puriﬁed the Ctr9-Paf1-Leo1 trimer
(Supplementary Fig. 1e). Taken together, these results show that
Paf1C contains a structured core and several ﬂexible regions
around its periphery.
TFIIS enhances Pol II-Paf1C binding. To investigate whether
puriﬁed Paf1C binds to yeast Pol II in vitro, we performed pull-
down assays using biotinylated Pol II coupled to streptavidin
beads (see Methods section). Paf1C interacted with Pol II, albeit
in a substoichiometric manner (Supplementary Fig. 2a, lane 4).
Considering the known interaction of human Paf1C with TFIIS45,
we tested whether TFIIS enhances Pol II-Paf1C binding. Indeed,
TFIIS strongly enhanced binding of Paf1C to Pol II in our assay
(Supplementary Fig. 2a, lane 5). In contrast, an N-terminal
deletion variant of TFIIS lacking 130 residues (TFIIS-DN130)
could not enhance Pol II-Paf1C interaction (Supplementary
Fig. 2b, lanes 7 and 8). These results suggest that the N-terminal
domain I of TFIIS, which is mobile in the Pol II-TFIIS
structure46, interacts with Paf1C to increase its afﬁnity to Pol
II. In addition, Paf1C lacking the C-terminal domain of Ctr9 and
Rtf1 retained Pol II binding (Supplementary Fig. 2c, lanes 6
and 8) and TFIIS-enhanced binding (Supplementary Fig. 2c, lanes
7 and 9). These results show that recombinant Paf1C interacts
with Pol II in vitro, that this interaction does not require Rtf1 and
that it is strongly enhanced by TFIIS (Supplementary Fig. 2d).
Cryo-EM analysis. To determine the structure of Paf1C bound to
a Pol II EC, we prepared a complex containing the complete 12-
subunit Pol II47, a DNA-RNA scaffold48, full-length TFIIS
carrying two point mutations that render it inactive in RNA
cleavage stimulation46,49 and recombinant Paf1C lacking the Ctr9
C terminus (Paf1C-Ctr9-DC913) (see Methods section), which is
more stable than Paf1C with full-length Ctr9. The complex
contained all 18 polypeptides in apparently stoichiometric
amounts after sucrose gradient ultracentrifugation (Fig. 2a).
After gradient ﬁxation50 (Supplementary Fig. 3a), the sample
contained single particles, as revealed by EM in negative stain
(Supplementary Fig. 3b), and was subjected to cryo-EM data
collection (see Methods section). A total of 2,741 micrographs
were collected on a Titan Krios equipped with a Gatan K2 direct
electron detection device (Supplementary Fig. 3c).
From the cryo-EM micrographs, a total of 947,597 particles were
extracted. Particle images were processed and subjected to reference-
free two-dimensional (2D) classiﬁcation in RELION51, yielding
370,841 particles after clearance. In several 2D classes, smeared
densities for the peripheral Paf1C and the Pol II stalk subcomplex
Rpb4-Rpb7 were observed on the polymerase surface (Fig. 2b). As a
reference, we used a reconstruction of bovine Pol II48 ﬁltered to low
resolution (50Å). After particle polishing in RELION, three-
dimensional (3D) classiﬁcation was used to separate out 158,422
particles that contained Pol II-TFIIS EC that lost Paf1C.
We reﬁned the remaining 212,419 Paf1C containing particles,
which led to a structure at 5.5Å global resolution that contained the
Pol II-TFIIS EC that closely resembled the crystal structure
(Supplementary Fig. 4). Although the polymerase, TFIIS and the
nucleic acids are very well deﬁned, the local resolution of different
parts of Paf1C is lower,B10–20Å, indicating ﬂexibility. A globally
ﬁltered 18Å resolution reconstruction of the Pol II-Paf1C-TFIIS EC
complex shows the location of Paf1C on the Pol II-TFIIS EC
(Fig. 2c). To improve Paf1C density, we performed sub-3D
classiﬁcation. This resulted in three different Pol II-Paf1C-TFIIS
EC reconstructions that we refer to as A, B and C (see
Supplementary Fig. 4 and Methods section). These reconstructions
showed average resolutions of 5.7, 5.9 and 6.2Å, respectively
(Fourier shell correlation (FSC)¼ 0.143; see Supplementary
Fig. 5a,b and Methods section) and enabled rigid-body ﬁtting of
the Pol II-TFIIS crystal structure49,52 and the DNA-RNA model48
(see Supplementary Fig. 5c,d and Methods section). The
reconstructions did not reveal structural changes within the Pol
II-TFIIS complex compared to the known crystal structure.
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Architecture of Pol II-Paf1C-TFIIS EC. Reconstructions A, B
and C revealed different portions of Paf1C on the Pol II surface that
we refer to as Paf1C parts A, B and C, respectively (Fig. 3a). The
observation that these three parts of Paf1C could only be observed
in different cryo-EM reconstructions shows that their relative
orientation is ﬂexible. Owing to this mobility on the Pol II surface,
the local resolution of Paf1C was low (Supplementary Fig. 5e–g).
When contoured at a level where no noise peaks are observed
(Fig. 3b), the volumes of parts A, B and C could account forB50,
45 and 90 kDa of folded protein (see Methods section). Because part
C overlaps with part A byB10 kDa, a total ofB175kDa of Paf1C
is visible by cryo-EM, corresponding toB50% of the total mass of
Paf1C, suggesting that most of the structured core (65%) is revealed
(Supplementary Fig. 1). We combined reconstructions A–C into a
composite map that is further interpreted below.
Paf1C binds to the outer surface of Pol II on the Rpb2 side,
spanning from the Rpb2 external 2 and protrusion domains to
subunit Rpb3 and reaching near the rim of the funnel opposite
the active centre cleft (Fig. 3a,b). Paf1C part A contacts mainly
the external 2 domain and likely the protrusion domain of Rpb2.
Part B contacts the protrusion and part C contacts Rpb11 and
Rpb3 around its helix a3. Part B also bridges between parts A and
C, which otherwise do not contact each other. Taken together,
cryo-EM revealed that the Paf1C core may be divided into three
parts, with parts A and C contacting Pol II at the Rpb2 lobe and
external 2 domains and Rpb3, respectively, and part B being
highly mobile and bridging between parts A and C.
Crosslinking analysis. To conﬁrm the contacts of Paf1C with Pol
II, and to assign Paf1C subunits to the three parts of Paf1C, we
subjected the Pol II-Paf1C-TFIIS EC to chemical crosslinking
coupled to mass spectrometry (XL-MS; see Methods section). We
used the crosslinking reagent bis(sulfosuccinimidyl) suberate
(BS3), which reacts with lysine side chains and N termini. In each
crosslinking data set, two replicates were measured. All the
spectra of the crosslinks were ﬁltered at a false discovery rate
cutoff of 1% and the maximum score value (negative logarithm of
E-value) 45. Each crosslink was required to have a minimal
spectral count of 2 in the two replicates of each data set (see
Methods section). We obtained 239 unique intersubunit cross-
links (Fig. 4a, Table 1 and Supplementary Data 1). We ﬁrst
mapped crosslinks between Pol II subunits and between Pol II
and TFIIS onto the Pol II-TFIIS EC crystal structure49. The
Ca–Ca distances between crosslinked residues were within the
allowed distances of 30Å for 35 out of 38 intersubunit pairs. The
other three crosslinks that showed longer Ca–Ca distances fell in
regions with structural ﬂexibility and higher crystallographic
B-factors (Fig. 4b,c and Supplementary Data 1). In addition, we
observed that Leo1 was crosslinked to two lysine residues (K78,
K80) in domain I of TFIIS, consistent with our pull-down assays
(see above). These results provided an internal, positive control
for our crosslinking approach, and demonstrated the proximity of
Paf1C to TFIIS.
Paf1C subcomplex architecture. The data also contained 136
intersubunit crosslinks within Paf1C (Fig. 4a, Table 1 and
Supplementary Data 1). These included 25 crosslinks between
Paf1 and Leo1, consistent with the known dimerization of Paf1
and Leo1 subunits. Crosslinks of the Leo1 residue K225 to Paf1












































Figure 2 | Reconstitution and cryo-EM analysis of Pol II-Paf1C-TFIIS EC. (a) SDS–PAGE analysis (Coomassie staining) of Pol II-Paf1C-TFIIS EC after
sucrose gradient ultracentrifugation. Subunits from Pol II and Paf1C are labelled in black and pink, respectively. The inactive variant of TFIIS is labelled in
green. The asterisk marks a degradation product of Rpb1. (b) Ten representative reference-free 2D cryo-EM class averages reveal the known ﬂexibility of
the Pol II stalk subcomplex Rpb4/7 (white arrow) and density for Paf1C (pink arrow). Scale bar, 10 nm. (c) Location of Paf1C on the Pol II-TFIIS EC.
A reconstruction of Pol II-Paf1C-TFIIS EC was reﬁned from 212,419 particles after the ﬁrst 3D classiﬁcation and globally ﬁltered to 18Å resolution. Density
for the Pol II-TFIIS EC subcomplex is shown in grey. Continuous Paf1C density at the outer surface of Pol II is shown in pink. The structure of the Pol II-TFIIS
EC is ﬁtted and shown in ribbon representation (non-template DNA, cyan; template DNA, blue; RNA, red, TFIIS, green; Rpb2 lobe, yellow; Rpb2 protrusion,
orange; Rpb2 external 2, green; Rpb3, red; Rpb11, yellow).
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X-ray structure. A total of 27 crosslinks were observed between
the Paf1-Leo1 dimer and Ctr9, revealing their proximity. The
subassembly Paf1-Leo1-Ctr9 crosslinked to the C-terminal
regions of Cdc73 and Rtf1. Consistent with this, the C-terminal
region of Rtf1 sufﬁces to bind Paf1C, because its coexpression
with the Paf1C core resulted in a stable complex (Supplementary
Fig. 1c). We also crosslinked free Paf1C and the obtained cross-
linking pattern was similar (Supplementary Data 1).
We also obtained 49 intersubunit crosslinks between Paf1C and
Pol II (Fig. 4a, Table 1, Supplementary Fig. 6 and Supplementary
Data 1). Forty-four of these crosslinks map to the Rpb2 lobe,
protrusion and external 2 domains, and subunits Rpb3 and Rpb11
(Supplementary Data 1), consistent with the location of Paf1C
observed by cryo-EM. The lysine-rich region (K298–K369) of Leo1
gives rise to many crosslinks to the protrusion, lobe and external 2
of Rpb2, which together with extensive crosslinking between the
Paf1-Leo1 dimer and the Pol II protrusion and lobe show that the
Paf1-Leo1 heterodimer resides in part A. Crosslinks between Cdc73
and Pol II subunits Rpb3 and Rpb11 reveal that Cdc73 resides in
part C. Indeed, part C contains a globular density that contacts
Rpb3 and corresponds in size to the crystal structure of the
C-terminal GTPase-like domain of Cdc73 (ref. 36) (Fig. 4d). We
could ﬁt this crystal structure to the globular density53 such that the
crosslinks between Cdc73 and Pol II were explained. Three
crosslinks occurred between the ﬁtted structure and Rpb3,
whereas Cdc73 residues in the adjacent N-terminal tail
crosslinked to the nearby Rpb11 subunit (Fig. 4d). Finally, Ctr9











































Paf1C - A Paf1C - B Paf1C - C
Figure 3 | Cryo-EM structure of Pol II-Paf1C-TFIIS EC. (a) Three reconstructions of Pol II-Paf1C-TFIIS EC after sub-3D classiﬁcation. Density for the Pol II-
TFIIS EC subcomplex is shown as a silver semitransparent surface. The electron densities for Paf1C are shown as a solid surface coloured in pink, magenta
and purple for Paf1C parts A, B and C, respectively. All three maps are unsharpened and ﬁltered according to local resolution. The ﬁtted structure of the Pol
II-TFIIS EC is shown in ribbon representation (non-template DNA, cyan; template DNA, blue; RNA, red, TFIIS, green; Rpb2 lobe, yellow; Rpb2 protrusion,
orange; Rpb2 external 2, green; Rpb3, red; Rpb11, yellow). (b) Two views of the composited EM density for the Pol II-Paf1C-TFIIS EC from three
reconstructions in a and the ﬁtted structure of the Pol II-TFIIS EC. These densities of locally ﬁltered Pol II and parts A–C are shown at the same threshold.
The view on the left is from the top80, and the view on the right is related by two rotations as indicated. The same threshold level in chimera was used to
contour densities.
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part A and Cdc73 in part C. Thus, Ctr9 bridges between Paf1-Leo1
and Cdc73, which both contact Pol II. Ctr9 did not crosslink
efﬁciently to Pol II, consistent with the bridging density B that
forms only limited contacts with the Pol II surface.
Combining the crosslinking data with the cryo-EM results and
our mapping of ﬂexible regions in Paf1C enabled us to derive the
overall architecture of Paf1C bound to Pol II. The sizes of the EM
densities can be reconciled with the Paf1C subunit molecular
weights as follows. Part A reveals only about half of the Paf1-Leo1
heterodimer (B50 out of 105 kDa), the other half is ﬂexible. Part
B reﬂects about half of the mass (B45 kDa) of Ctr9-DC913
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Figure 4 | Crosslinking analysis of Pol II-Paf1C-TFIIS EC. (a) Network diagrams of pairwise crosslinks (black lines) obtained after incubation of Pol II-
Paf1C-TFIIS EC with BS3. The left diagram depicts intersubunit crosslinks between Pol II and Paf1C, Pol II and TFIIS, and between Paf1C and TFIIS. The right
diagram depicts crosslinks between Paf1C subunits. Crosslinks between Pol II subunits were excluded for clarity. Paf1C subunits coloured as in Fig. 1. In
addition, the regions of protrusion, lobe and external 2 in Rpb2 are indicated with orange, yellow and green bars below Rpb2 diagram, respectively.
(b) Ca–Ca distance distribution of observed Pol II-Pol II and Pol II-TFIIS crosslinks for lysine residues that were resolved in the Pol II-TFIIS crystal structure.
These crosslinks serve as a positive control for our crosslinking data. Asterisks indicate crosslinks to ﬂexible protein regions. (c) Crosslinks between Pol II
and TFIIS (black lines) are consistent with the known Pol II-TFIIS complex crystal structure. Colour coding as in Fig. 3. (d) Position of the Cdc73 C-terminal
GTPase-like domain (purple) contacting Rpb3. The crystal structure of the GTPase-like domain was docked into density of the correct size and oriented
according to crosslinks to Rpb3 and Rpb11 (black lines). Paf1C density is shown in mesh in the same orientation as in Fig. 3. View is from the top. The
distances between site of crosslinking in Cdc73 and Rpb3/Rpb11 are revealed. The distance between K263 of Cdc73 and K199 of Rpb1 in this ﬁt is 18.5Å.
the distances between K236 and K385 in the Cdc73 GTPase-like domain structure and K55 of Rpb11 are around 40Å due to the ﬂexibility of both terminal
regions of the GTPase-like domain.
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is much larger than the Cdc73 GTPase-like domain alone
(B20 kDa). Finally, Rtf1 (65 kDa) remains ﬂexible.
Competitive Pol II binding of Paf1C and TFIIF. Superposition
of the Pol II-Paf1C-TFIIS EC onto our previously reported Pol II
initiation complex structure54 reveals a clash between Paf1C part
A and the dimerization domain of the initiation factor TFIIF
bound to the outer lobe of Pol II at an overlapping position
(Fig. 5a). This suggested that Paf1C and TFIIF may bind to Pol II
in a competitive manner. To investigate this, we performed
binding assays using analytical sucrose gradient
ultracentrifugation (see Methods section). We incubated
preformed Pol II-Paf1C-TFIIS complex with a 1.8-fold molar
excess of TFIIF and separated the resulting complexes on a
10–30% sucrose gradient. Based on subsequent SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) analysis, we
estimate that TFIIF replaced Paf1C in about half of the Pol II
complexes (Fig. 5b). When we instead incubated preformed Pol
II-TFIIF complex with Paf1C and TFIIS, some TFIIF was
displaced, TFIIS was able to join the complex and Paf1C bound
to a low extent (Fig. 5c). Analysis of the relevant gradient
fractions by native PAGE shows that TFIIF can almost completely
compete off the Pol II-bound Paf1C, but not the other way
around (Fig. 5d,e). These results indicate that Paf1C and TFIIF
bind to Pol II in a competitive manner, consistent with the cryo-
EM reconstruction.
Paf1C is globally required for Pol II transcription. Thus far, it
had not been demonstrated whether Paf1C is a general tran-
scription factor in yeast. To investigate whether Paf1C is globally
required for transcription in vivo, or whether it has gene-speciﬁc
functions, we monitored RNA synthesis with 4-thiouracil-Seq
(4tU-Seq) in yeast55–57. This method uses metabolic RNA
labelling with 4tU coupled to strand-speciﬁc sequencing of
labelled, newly synthesized RNA. We used 4tU-Seq to monitor
RNA synthesis in strains lacking either Paf1 (paf1D) or Rtf1
(rtf1D), and compared this to a wild-type strain using global
normalization based on spike-in probes58. Two biological
replicates were measured. We found that knockout of Paf1 or
Rtf1 led to a strong, global decrease in synthesis of mRNA
transcripts (Fig. 6a), showing that Paf1C is globally required for
normal Pol II transcription. Furthermore, the analysis of
signiﬁcantly downregulated transcripts in paf1D and rtf1D
strains with a Venn diagram shows strong overlap between
paf1D and rtf1D strains, but that the rtf1D strain shows 35% more
downregulated RNAs, consistent with the idea that Rtf1 has
Paf1C-independent roles34 (Fig. 6b).
Discussion
Here, we use a combination of cryo-EM and crosslinking to show
that Paf1C forms a tripartite architecture. Parts A and C contain
Paf1-Leo1 and Cdc73, respectively, and contact Pol II near the
Rpb2 external 2 domain and Rpb3, respectively. Ctr9 forms part
B and extends into part C, forming a ﬂexible bridge between parts
A and C that is not directly contacting Pol II. These results
explain published data. Ctr9 has been predicted from biochemical
data to form a scaffold that bridges between Paf1-Leo1 and Cdc73
(ref. 38). The Cdc73 GTPase-like domain binds Pol II, consistent
with the requirement for this domain to recruit Paf1C to
chromatin36. The C-terminal region of Cdc73 (201–393 amino
acids) has been reported to bind the Pol II C-terminal domain35,
but this region could not be localized here. Most of Rtf1 is
ﬂexible, including the Plus3 domain that binds the
phosphorylated CTR of Spt5 (ref. 41), which is also ﬂexibly
connected to the EC. Our results also explain how Paf1C and
TFIIS can cooperatively bind to Pol II45. Pull-down assays show
that TFIIS facilitates Pol II-Paf1C binding via its domain I.
Correspondingly, we observe crosslinking between Leo1 and
TFIIS domain I, and this interaction occurs near the jaw-lobe
module of Pol II. We arrive at an overall architecture of the Paf1C
on the Pol II EC that explains known interactions (Fig. 7).
Table 1 | Summary of BS3 crosslinks in Pol II-Paf1C-TFIIS EC.
Protein 1 Protein 2 Unique crosslinks BS3





















Pol II Pol II 47
Pol II TFIIS 5
Total 239
BS3, bis(sulfosuccinimidyl) suberate; EC, elongation complex; Paf1C, polymerase-associated factor 1 complex; Pol II, polymerase II.
The number of interprotein crosslinks are given. Interprotein crosslinks between Pol II subunits are not shown here for clarity. Each unique crosslink is identiﬁed by more than one crosslink. BS3 is a
crosslinker with 11.4Å spacer arm and reacts efﬁciently with amino groups (lysine and N terminus).
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Figure 5 | Paf1C and TFIIF compete for Pol II binding. (a) Positioning the initiation factor TFIIF dimerization domain as in the Pol II initiation complex (PDB
accession: 5FYW)54 onto the Pol II-Paf1C-TFIIS EC cryo-EM reconstruction results in a clash of TFIIF with Paf1C (top view). Colours as in Fig. 3. The TFIIF
dimerization domain is coloured in medium purple (TFIIF subunit Tfg1) and plum (Tfg2). A close-up view of the clashing region is shown on the right.
(b,c) SDS–PAGE analysis of TFIIF and Paf1C competitive binding to Pol II after analytical sucrose gradient ultracentrifugation. In each panel, the gels on the
left depict complexes without competitor protein. The gels on the right represent complexes formed after competitor addition. In b, a 1.8-fold molar excess
of TFIIF was added to preformed Pol II-Paf1C-TFIIS EC. In c, Paf1C-TFIIS was added to preformed Pol II-TFIIF complex. (d,e) Native PAGE analysis of
indicated fractions from the analysis in b. In our minimal in vitro system, TFIIF is able to largely compete out Paf1C. The identity of the proteins in the
indicated complexes was conﬁrmed by mass spectrometry.
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We further show that Paf1C is generally required for
transcription in vivo, and thus our results elucidate aspects of
the general transcription cycle. In particular, they provide insights
into the transition from transcription initiation to elongation,
when initiation factors are replaced by elongation factors on the
Pol II surface29,59,60. We suggest that in the initiation complex,
Paf1C cannot bind Pol II because the site for binding part A is
occupied by TFIIF, which binds the lobe. Similarly, TFIIE blocks
the site for binding the elongation factor Spt4-Spt5 on the
clamp61,62. These observations explain why Paf1C and Spt4-Spt5
bind the EC only upon disassembly of the initiation complex.
These elongation factors appear to bind Pol II weakly in isolation,
but interactions between them32,33 and between Paf1C and
TFIIS45 may enhance their polymerase association. We note that
the second contact of Paf1C with Pol II, formed between part C
and Rpb3, does not overlap with known factor positions on Pol II.
This contact may therefore help to retain Paf1C in the EC when
TFIIF reassembles during elongation63.
Despite our success in obtaining structural information on the
highly ﬂexible EC containing Paf1C, the mechanisms Paf1C uses
to facilitate chromatin transcription remain unclear. Insights into
the mechanisms of chromatin transcription will only come from a
structural analysis of the interface of Paf1C with nucleosomes
and other chromatin-associated factors. This poses a highly
formidable challenge for the future. In the meantime, our results
provide the overall Paf1C architecture and location on the
polymerase, elucidate the molecular basis for transcription factor
exchange during the initiation–elongation transition, and provide
a framework for further dissection of the multiple functions of
Paf1C in transcription.
Methods
Paf1C expression and puriﬁcation. The gene sequences encoding for Ctr9, Rtf1
and Cdc73 were ampliﬁed from the S. cerevisiae genomic DNA by polymerase
chain reaction (PCR). Open reading frames of Paf1 and Leo1 were chemically
synthesized by GeneArt (Thermo Fisher Scientiﬁc) to optimize codon usage for
more efﬁcient bacterial expression. Full-length Ctr9 was cloned into pET24b
(Novagen) resulting in a non-cleavable hexahistidine tag fused to the Ctr9 carboxyl
terminus. The PCR products of full-length Rtf1 or Cdc73 were cloned into an in-
house modiﬁed version of the pET21b vector (Novagen). Ribosome binding
sequence-Cdc73, which contains an ribosome binding sequence on the amino
terminus of Cdc73 was inserted sequentially after Rtf1. Additionally, Cdc73 was
cloned into multiple cloning sites 2 of pETDuet-1 (Novagen) for the coexpression
of a four-subunit Paf1 complex lacking Rtf1 (Paf1C-DRtf1). Leo1 and Paf1 were
PCR ampliﬁed and cloned into two multiple cloning sites of pCDFDuet-1 vector
(Novagen) separately and sequentially. The ﬁve-subunit Paf1C and its variants
were heterologously coexpressed in E. coli BL21 CodonPlus(DE3)RIL cells (Stra-
tagene). Cultures of bacteria transformed with pET24b-Ctr9 and pCDFDuet-1-
Leo1-Paf1 were grown in Luria–Bertani medium at 37 C to an OD600 nm ofB0.8.
The temperature was reduced to 18 C, and protein overexpression was induced by














































Figure 6 | Paf1C is globally required for Pol II transcription in yeast. (a) Left panel: coverage of newly synthesized RNA measured by 4tU-Seq in WT
(solid blue line), rtf1D (dashed red line) and paf1D yeast cells (dashed green line). 4tU-Seq signals were globally normalized using spike-in probes. The gene
body is deﬁned as the region spanning from the transcription start site (TSS) to the pA site and is depicted as a grey box. Right panel: box plot showing the
expression fold change of read counts for paf1D and rtf1D versus the wild-type (WT) strain. Dashed lines indicate median fold (0.52 for paf1D and 0.23 for
rtf1D). The majority of mRNAs have signals below 1 (indicated by the solid black line). mRNA transcripts that are downregulated make up 85% for paf1D
and 94% for rtf1D of all mRNAs with a coverage of at least 2 in the WT strain. (b) Analysis of signiﬁcantly downregulated transcripts in paf1D and rtf1D
strains using a Venn diagram. Most of the downregulated transcripts in paf1D (4,607 out of 4,733) strain are also affected by the rtf1D mutation, although
2,640 transcripts are uniquely downregulated in the rtf1D strain.
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18 C overnight. The same strategy was used for the coexpression of Rtf1 and
Cdc73.
Cells were collected and colysed by sonication in buffer A (50mM Tris (pH
8.7), 600mM potassium acetate (KOAC), 2mM dithiothreitol (DTT), 2mM
MgCl2, 10mM imidazole, 10mM ZnCl2) containing a 1:100 dilution of protease
inhibitor cocktail (1mM leupeptin, 2mM pepstatin A, 100mM
phenylmethylsulfonyl ﬂuoride, 280mM benzamidine), 1,000U benzonase and
0.4 mgml 1 DNaseI. The extract was cleared by centrifugation (20 000g, 30min)
and the supernatant was loaded onto a 2-ml Ni-NTA agarose bead column
(Qiagen), equilibrated in buffer A. The column was washed extensively with buffer
A containing 20mM imidazole. The complex was eluted with buffer A containing
150mM imidazole. The eluted protein was diluted 10-fold and was further puriﬁed
by cation exchange chromatography using a 1-ml HiTrap SP HP column (GE
Healthcare). The column was equilibrated in buffer B (50mM Tris (pH 8.7),
70mM KOAC, 2mM MgCl2, 2mM DTT, 10 mM ZnCl2) and proteins were eluted
with a linear gradient from 70mM to 2M KOAC in buffer B. Fractions containing
the protein of interest were concentrated and loaded onto a Superose 6 10/300 (GE
Healthcare) size-exclusion chromatography column equilibrated with buffer C
(10mM Tris (pH 8.5), 200mM NaCl, 2mM MgCl2, 2mM DTT, 10mM ZnCl2) or
buffer D (10mM HEPES (pH 7.5), 100mM NaCl, 2mM MgCl2, 2mM DTT,
10mM ZnCl2). The protein complex was concentrated by centrifugation in Amicon
Ultra 4-ml concentrators (molecular weight cutoff¼ 50 kDa; Millipore) to
3mgml 1. Protein was aliquoted, ﬂash frozen in liquid nitrogen and stored at
 80 C. The similar strategy was used for purifying the ﬁve-subunit Paf1C
variants.
The four-subunit Paf1 complex (Paf1C-DRtf1) and its variants were expressed
and puriﬁed as described for the ﬁve-subunit complex (Paf1C), except that we
cotransformed pET24b-Ctr9, pCDFDuet-1-Leo1-Paf1 and pETDuet-1-Cdc73
plasmids together in E. coli BL21 CodonPlus (DE3) RIL cells. All the components
were separated by SDS–PAGE and conﬁrmed by mass spectrometry.
Limited proteolysis and Edman sequencing. Limited proteolysis experiments
were performed in buffer C (10mM Tris (pH 8.5), 200mM NaCl, 2mM MgCl2,
2mM DTT, 10 mM ZnCl2) containing 1.6mgml 1 Paf1C and different con-
centration of respective protease. A measure of 0.04–0.4 ng ml 1 subtilisin,
1–10 ng ml 1 trypsin and 2 ng ml 1 ArgC were incubated with Paf1C at room
temperature for 2min, 2min and a 5–20min time course, respectively. The reac-
tions were stopped using SDS loading buffer. Samples were analysed by SDS–
PAGE. The separated limited proteolysis products on the SDS gel were blotted onto
a polyvinylidene diﬂuoride membrane. The membrane was stained with Ponceau S
before the fragments were excised and sequenced using a Procise cLC (Applied
Biosystems, Foster City, CA, USA).
Pull-down assay. Pol II containing a biotin acceptor peptide at the N terminus of
Rpb3 was puriﬁed. Enzymatic biotinylation was carried out in vitro in 100ml
reactions containing 124mg of Pol II, 8 mg BirA, 2mM ATP and 100 mM biotin
supplemented with dilution buffer (20mM HEPES (pH 7.5), 16mM MgCl2, 10mM
ZnCl2, 10mM DTT). The mixture was incubated for 2 h in a thermomixer at 20 C
and 600 r.p.m. Buffer exchange to Pol II buffer (5mM HEPES (pH 7.5), 10 mM
ZnCl2, 40mM (NH4)2SO4, 10mM DTT) was carried out using Micro Bio-SpinTM
Chromatography columns (Bio-Rad). In each pull-down assay, 5.8 mg biotinylated
Pol II was immobilized on 20 ml Dynabeads M-280 streptavidin resin (Thermo
Fisher Scientiﬁc), equilibrated in buffer P (50mM HEPES (pH 7.5), 0.1% NP-40,
150mM KOAC, 2mM DTT). Fivefold molar excess of puriﬁed Paf1C or/and TFIIS
were incubated with immobilized Pol II or control resin at 4 C for 1 h. Beads were
washed ﬁve times. Input and the bound proteins were subjected to SDS–PAGE
analysis. Relative binding fold changes between Pol II and Paf1 complexes when
TFIIS or TFIIS-DN130 presents were quantiﬁed using Image J. The amount of Leo1
(Paf1C subunit) is quantiﬁed relative to the amount of Pol II (subunit Rpb4) in
each lane. The fold change is set to 1 in cases lacking TFIIS (representing
unchanged amounts). Error bars indicate the s.e.m. from three replicates.
EC preparation. The nucleic acid scaffold (Integrated DNA Technologies) used for
transcribing mammalian RNA Pol II48, which contains an 11 nucleotide mismatch
transcription bubble and 20 nucleotide RNA (bubble-RNA) was used to assemble
Pol II-Paf1C-TFIIS EC (template DNA sequence 50-AAGCTCAAGTACTTA
AGCCTGGTCATTACTAGTACTGCC-30, non-template DNA sequence 50-
GGCAGTACTAGTAAACTAGTATTGAAAGTACTTGAG CTT-30 and RNA
sequence 50-UAUAUGCAUAAAGACCAGGC-30). Equimolar amounts of DNA
and RNA were mixed and annealed in a Biometra T3000 Thermocycler that heated
to 95 C and cooled in 1 C increments every 30 s until 10 C were reached. The Pol
II-bubble-RNA was assembled by incubating 250 pmol puriﬁed Pol II with
equimolar bubble-RNA in Pol II buffer for 10min at 25 C. A 1.8-fold molar excess
of Paf1C-Ctr9-DC913 and a 1.8-fold molar excess of TFIIS (DE-AA)-inactive







































Figure 7 | Model of the Pol II EC with bound elongation factors. Summary of our current understanding of elongation factor location and interactions on
the Pol II EC surface. In addition to direct Pol II interactions by domains in TFIIS, Spt5 and Paf1C, elongation factors contain many ﬂexible domains and
regions that interact. In particular, the Paf1-Leo1 heterodimer may contact the N-terminal domain I of TFIIS and the C-terminal region of Rtf1 is anchored to
Paf1C mainly by Paf1 and Ctr9 subunits shown in XL-MS, whereas its Plus3 domain binds the ﬂexible CTR of Spt5. The N-terminal tail of Rtf1 is important for
recruiting the chromatin remodeller Chd1 (ref. 9). Dashed lines in this model indicate ﬂexible regions.
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HEPES (pH 7.5), 100mM NaCl, 2mM MgCl2, 2mM DTT, 10mM ZnCl2) for
15min at 20 C in a 65 ml reaction volume. We then centrifuged the reaction for
10min at 4 C at 15,000 r.p.m. and kept the supernatant for size-exclusion
chromatography or gradient ﬁxation (GraFix) before XL-MS or EM, respectively.
Crosslinking and mass spectrometry analysis. The assembled Pol II-Paf1C-
TFIIS complex was injected onto size-exclusion chromatography to obtain a
homogeneous complex. The fractions containing target complex were collected and
crosslinked at various concentrations of BS3 (Thermo Fisher Scientiﬁc) to deter-
mine empirically the optimal reaction conditions. The best condition, 0.5mM BS3,
was sufﬁcient to convert most of individual component into a high-molecular-
weight band in SDS–PAGE and was chosen for ﬁnal sample preparation. The Pol
II-Paf1C-TFIIS at a concentration of 425 mgml 1 was crosslinked with 0.5mM
BS3 and incubated for 30min at 30 C. The reaction was quenched by adding
50mM ammonium bicarbonate. The crosslinked sample was repuriﬁed by size-
exclusion chromatography on a Superose 6 PC 3.2/300 column (GE Healthcare)
equilibrated in buffer D (10mM HEPES (pH 7.5), 100mM NaCl, 2mM MgCl2,
2mM DTT, 10 mM ZnCl2). Crosslinked sample was digested with trypsin.
Crosslinked peptides were enriched and divided into two parts. Both halves of
the sample were measured on an Orbitrap Fusion LC-MS/MS instrumentation
platform (Thermo Fisher Scientiﬁc) and the data sets were analysed with pLink
1.23 (ref. 64) against a database containing the sequences of the proteins
components in the complex separately. An initial false discovery rate cutoff of 1%
was set. E-value was calculated in this processing. To visualize this score better, the
negative logarithm of E-value was used. The ﬁnal set of crosslinks were required to
satisfy 3 criteria: (1) appeared in both replicates; (2) the max score value from each
data set was higher than 5; (3) each crosslink must have a minimal spectral count of
2 in each data set. The ﬁnal result was subsequently visualized using the xiNET
online server65. The same strategy was used for Paf1C XL-MS, except that the
samples were measured on an AB Sciex Triple-ToF instrument (AB SCIEX).
Gradient ﬁxation. To reconstitute a homogeneous Pol II-Paf1C-TFIIS EC, the
sucrose GraFix was carried out as described50. Each sucrose gradient for GraFix
was generated by mixing equal volumes of light solution (10mM HEPES (pH 7.5),
100mM NaCl, 2mM DTT, 2mM MgCl2, 10 mM ZnCl2, 10% (w/v) sucrose) and
heavy solution 1 (10mM HEPES (pH 7.5), 100mM NaCl, 2mM DTT, 2mM
MgCl2, 10mM ZnCl2, 30% (w/v) sucrose, 0.075% (w/v) glutaraldehyde) using a
gradient mixer (Gradient Master 108; BioComp Instruments). This resulted in a
dual gradient of 10–30% sucrose and 0–0.075% glutaraldehyde in an 11 60mm2
ultracentrifuge tube (Beckman Coulter). Next, 60 ml of the in vitro reconstituted Pol
II-Paf1C-TFIIS EC were applied on top of the gradient. After ultracentrifugation at
32,000 r.p.m. in a SW60 swinging bucket rotor (Beckman Coulter) for 16 h at 4 C,
200ml fractions of the gradient were collected by pipetting carefully from top to
bottom of the tube. Parallel sucrose gradient fractions of samples applied to
gradients either containing or lacking glutaraldehyde showed the same
sedimentation proﬁle when analysed by SDS–PAGE. The crosslinking reaction was
quenched by adding 0.5M (pH 7.8) aspartate to a ﬁnal concentration of 12.5mM.
Micro spin chromatography columns (Bio-Rad) were used for buffer exchange to
remove sucrose, glutaraldehyde and aspartate. The samples were concentrated
using a GE concentrator (molecular weight cutoff¼ 100 kDa; GE Healthcare) and
immediately used for cryo-EM.
Negative stain EM. Pol II-Paf1C-TFIIS EC was prepared as described above.
Negative staining of the specimen was carried out as described48. Micrographs were
obtained using an FEI Philips CM-200 at 160 kV with a original magniﬁcation of
 88 000 (corresponding to a calibrated sampling of 2.51Å per physical pixel) and
a defocus B2.0 mm.
Cryo-EM specimen preparation and data acquisition. An FEI Vitrobot Mark IV
plunger (FEI) was used for preparation of frozen-hydrated specimens. Four
microlitres of sample was placed onto Quantifoil Cu R3.5/1 and Cu R2/1 glow-
discharged 200 mesh holey carbon grids, which were then blotted for 8.5 s with blot
force 13 to remove the excess solution before they were ﬂash frozen in liquid
ethane. The Vitrobot chamber was operated at constant 4 C and 100% humidity
during blotting. The grids were transferred and stored in liquid nitrogen before
data acquisition.
Two cryo-EM data sets were acquired on a 300 keV FEI Titan Krios electron
microscope equipped with a K2 Summit direct electron counting camera (Gatan)
positioned post a GIF Quantum energy ﬁlter (Gatan) to increase the signal-to-noise
ratio. Automated data collection was carried out using the TOM toolbox66. Movie
images were recorded at a nominal magniﬁcation of  37,000 (corresponding to a
calibrated sampling of 1.35 Å per physical pixel) in super-resolution mode, thus
yielding a pixel size of 0.675Å per pixel. For the ﬁrst data set, two movies were
acquired in each hole and a total of 595 movie stacks with a defocus range of  0.7
to  4.2 mm were collected from Quantifoil Cu R3.5/1 grids at a dose rate of 7.6
electrons per pixel per second. Each movie encompassed a total dose of B33
electrons per Å2 with a total exposure time of 10.8 s fractionated into 27 frames.
Each frame had an exposure time of 0.4 s. For the second data set collected from
the Quantifoil Cu R2/1 grids, one movie was acquired in each hole and 2,146 movie
stacks were recorded with an exposure time of 12 s fractionated into 30 frames, a
dose rate of 4.2 electrons per pixel per second. Each frame had an exposure
time of 0.4 s, resulting in a total accumulated dose of B28 electrons per Å2 per
stack. Defocus values ranged from  0.6 to  4.2 mm. Movie stacks from two data
sets were aligned and binned as previously described with the frame-based motion-
correction algorithm to generate drift-corrected micrographs for further
processing67, except images were not partitioned into quadrants.
Cryo-EM image processing. Contrast transfer function was estimated using
CTFFIND3 (ref. 68) and CTFFIND4 (ref. 69) for the data sets from Quantifoil Cu
R3.5/1 grids (R3.5) and Quantifoil Cu R2/1 grids (R2), respectively. For the R3.5
data set, 123 aligned micrographs were excluded because of contaminations or bad
ice quality. After removing these micrographs, we used e2boxer.py from EMAN2
package70 to semiautomatically pick 84,362 particles with a box size of 2402 pixels
from the remaining micrographs. 2D reference-free classiﬁcation within RELION
1.4 (ref. 51) was used to remove micelles or other false positives. After this step
79,024 particles remained. We deleted 512 aligned micrographs from the R2 data
set and semiautomatically picked 21,301 particles using e2boxer.py from EMAN2
package with a box size of 2402 pixels.
Reference-free 2D classes were generated, and nine representative classes were
low-pass ﬁltered to 20Å and used as templates for autopicking71. The resulting
863,235 particles were screened manually and subjected to reference-free 2D
classiﬁcation, yielding 291,817 particles. We then merged particles from two
datasets. 370,841 particles were used as an input for the subsequent 3D
reconstruction performed with RELION 1.4 (ref. 51), unless noted otherwise.
A published reconstruction of bovine Pol II48 ﬁltered to 50Å was used as an initial
reference for 3D reﬁnement. The aligned particles were subjected to particle
polishing using RELION 1.4 (ref. 72) to reduce the noise and correct the local
motion and radiation damage.
3D classiﬁcations were carried out without image alignment. The ﬁrst 3D
classiﬁcation was performed to separate out particles lacking the Paf1C density.
This led to the dismissal of 158,422 particles. We reﬁned the remaining 212,419
Paf1C-containing particles. Gold-standard FSC was calculated after the 3D
reﬁnement in RELION. A 5.5Å average resolution map was observed at the gold-
standard FSC criteria of 0.143. In the second step, a soft mask encompassing Paf1C
was generated using the ‘volume erase’ option in UCSF Chimera53 and RELION51.
After 3D classiﬁcation within this mask, we obtained three Pol II-Paf1C-TFIIS
maps resolving different parts of Paf1C density (parts A, B and C). The individual
classes were autoreﬁned using the respective masks. The complex containing part A
was reﬁned from 114,672 particles to an average resolution of 5.7 Å. The complex
containing part B was reﬁned from 54,722 particles to an average resolution of
5.9 Å. The complex containing part C was reﬁned from 43,025 particles to an
average resolution of 6.2 Å. All three maps were unsharpened and ﬁltered
according to local resolution73. All structural ﬁgures were generated using UCSF
Chimera53 and PyMOL (Schro¨dinger LLC.).
Structural modelling. The X-ray crystallographic structure of the Pol II-TFIIS
complex (PDB entry: 3PO3; ref. 49) was used as the starting reference model and
placed into the cryo-EM map using UCSF Chimera53. Amino acids 68–89 and
132–168 of the protrusion domain of Rpb2 were replaced by the coordinates from
the PDB entry 5C4J52. Template DNA (nucleotides 1–33), non-template DNA
(nucleotides 7–39) and RNA (nucleotides 7–20) were derived from the PDB entry
5FLM (ref. 48). The models were ﬁtted as rigid bodies into the density map using
‘Fit in Map’ in UCSF Chimera53. The C-terminal GTPase-like domain of Cdc73
(PDB entry: 3V46) was ﬁtted into the map of the complex containing part C using
UCSF Chimera53 and adjusted in COOT74 based on the XL-MS results. We also
calculated the approximate molecular weight of the density, which is present in
addition to Pol II, with Chimera using TFIIS as a reference53.
Analytical sucrose gradient ultracentrifugation. To investigate the binding of
TFIIF and Paf1C to Pol II, analytical sucrose gradient ultracentrifugation was
carried out. A sucrose gradient was generated by mixing equal volumes of light
solution (10mM HEPES (pH 7.5), 100mM NaCl, 2mM DTT, 2mMMgCl2, 10mM
ZnCl2, 10% (w/v) sucrose) and heavy solution 2 (10mM HEPES (pH 7.5), 100mM
NaCl, 2mM DTT, 2mM MgCl2, 10 mM ZnCl2, 30% (w/v) sucrose) using a gradient
mixer (Gradient Master 108; BioComp Instruments).
Reconstituted Pol II-Paf1C-TFIIS EC was divided into portions. The ﬁrst
portion was incubated with a 1.8-fold molar excess of TFIIF54, while the other
portion was incubated with buffer D (10mM HEPES (pH 7.5), 100mM NaCl,
2mM MgCl2, 2mM DTT, 10mM ZnCl2) as a control. Next, the reconstituted
complexes were applied on top of the gradient. After ultracentrifugation at
32,000 r.p.m. in a SW60 swinging bucket rotor (Beckman Coulter) for 16 h at 4 C,
200 ml fractions were collected by pipetting carefully from top to bottom of the tube
before analysing them by SDS–PAGE and native PAGE. The assay was repeated
but starting from a Pol II-TFIIF complex and then incubating with excess Paf1C-
TFIIS.
4tU-Seq data collection. 4tU labelling of cellular RNA was performed as
described75 with minor changes. Forty microlitres of each replicate culture were
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used for metabolic RNA labelling. The strains used in this study paf1D (MATa
his3D1 leu2D0 met15D0 ura3D0 paf1::kanMX) and rtf1D (MATa his3D1 leu2D0
met15D0 ura3D0 rtf1::kanMX) were purchased from Euroscarf. Yeast cells were
grown in yeast extract peptone dextrose medium overnight, diluted to an OD600 nm
of 0.1 and grown to an OD600 nm of 0.8. 4tU (Sigma; 2M in dimethylsulfoxide) was
added to the media at a ﬁnal concentration of 5mM, and cells were collected after
6min of labelling by centrifugation at 2,465g and 30 C for 1min. The supernatant
was discarded and the pellet resuspended in RNAlater solution (Ambion/Applied
Biosystems) and then ﬂash frozen in liquid nitrogen. Cell number was determined
from an aliquot with a Cellometer N10 (Nexus) cell counter. Total RNA was
extracted with phenol chloroform. RNA spike-ins were added to cell pellets at the
ﬁrst step of RNA puriﬁcation58. Brieﬂy, six artiﬁcial RNAs (spike-ins: ERCC-00043,
ERCC-00170, ERCC-00136, ERCC-00145, ERCC-00092 and ERCC-00002) from
the ERCC RNA spike-in mix (Life Technologies) were mixed in equal amount to all
samples. Each spike-in was subjected to in vitro transcription beforehand with the
Megascript T7 Transcription Kit (Life Technologies) with either 1:10 4sUTP:UTP
ratio for spike-ins ERCC-00043, ERCC-00136 and ERCC-00092 or only UTP for
spike-ins ERCC-00170, ERCC-00145 and ERCC-00002; resulting in labelled and
non-labelled spike-ins, respectively. The amount of spike-ins was adjusted to the
cell number of each sample (120 ng of spike-in mix to 2.5 108 cells for all
samples). Labelled RNA was chemically biotinylated and puriﬁed using
strepatavidin-coated magnetic beads as described76. Sequencing libraries were
prepared according to the manufacturer’s recommendations using the Ovation
Universal RNA-Seq System (NuGEN). Libraries were quantiﬁed with Qubit 1.0.
Libraries were pooled and sequenced on an Illumina HiSeq 2500 sequencer.
4tU-Seq data analysis. Data analysis was performed as described57, with minor
modiﬁcations. Brieﬂy, paired-end 50 bp reads with additional 6 bp of barcodes were
obtained for labelled RNA. Reads were demultiplexed and aligned to the
S. cerevisiae genome (sacCer3, version 64.2.1) using STAR (version 2.3.0)77.
SAMTools was used to quality ﬁlter SAM ﬁles77. Alignments with MAPQ smaller
than 7 ( q 7) were skipped and only proper pairs ( f99,  f147,  f83,  f163)
were selected. Further processing of the RNA-Seq data was carried out using the R/
Bioconductor environment. Piled-up counts for every genomic position were
summed up over replicates, using physical coverage, that is, counting both
sequenced bases covered by reads and unsequenced bases spanned between proper
mate-pair reads. We used a spike-in (RNAs) normalization strategy as described
before58 to allow for observation of global changes in the 4sU-Seq signal. Read
counts for all spike-ins necessary to that end were calculated using HTSeq78 after
mapping. To estimate these normalization factors, we used a statistical model that
describes the read counts for each gene in each sample by gene-speciﬁc amounts of
labelled RNA. The model includes a parameter for the length of the respective
feature. The expectation of the number of reads is ﬁtted by maximum-likelihood
assuming negative binomial distribution with dispersion parameters as calculated
by DESeq79.
Data availability. The cryo-EM data has been deposited in Electron Microscopy
Data Bank (EMDB) under accession codes EMD-3626, EMD-3627, EMD-3628 and
EMD-3629 for the RNA polymerase II-Paf1C-TFIIS, RNA polymerase II-Paf1C-
TFIIS-A, -B and -C structures, respectively. The sequencing data and the anno-
tation ﬁle have been deposited in the Gene Expression Omnibus database under
accession code GSE95556. The data that support the ﬁndings of this study are
available from the corresponding author on request.
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